Reading Time: 1 minute
Shareholders of Pfizer Inc. (PFE) have faced difficulties following the decline of the COVID-19 vaccine boom. During the pandemic, Pfizer profited immensely from the sales of the COVID-19 vaccine Comirnaty and the antiviral drug Paxlovid. However, as the pandemic subsided, these revenues have significantly decreased, leading to a massive drop in total earnings. Additionally, the expiration of patents adds to the pressure. The company is facing a so-called "patent cliff," where patents for several high-revenue drugs are set to expire. This allows...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
